ASTEC LIFESCIENCES LTD.
NSE : ASTECBSE : 533138ISIN
CODE : INE563J01010Industry : Pesticides & AgrochemicalsHouse
: Godrej
BSE1298.0010.35 (+0.8 % )
PREV CLOSE (Rs.) 1287.65
OPEN PRICE (Rs.) 1312.60
BID PRICE (QTY) 1298.00 (23 )
OFFER PRICE (QTY) 1300.65 (8 )
VOLUME 12151
TODAY'S LOW / HIGH (Rs.)
52 WK LOW / HIGH (Rs.)
NSE1298.50 14.1 (+1.1 % )
PREV CLOSE(Rs.) 1284.40
OPEN PRICE (Rs.) 1316.95
BID PRICE (QTY) 1298.50 (10 )
OFFER PRICE (QTY) 1300.00 (6 )
VOLUME 140973
TODAY'S LOW / HIGH(Rs.)
52 WK LOW / HIGH (Rs.)
Company News
| Date | Heading | Details |
|---|---|---|
| 19-Apr-2024 | Astec LifeSciences informs about closure of trading window | <p style="text-align: justify;">Astec LifeSciences has informed that the trading window will remain closed for some of the Designated Persons beyond the declaration of the Audited Financial Results of the Company for the Quarter and Financial Year ended March 31, 2024 and until further intimation by the Company. The concerned Designated Persons of the Company have accordingly been intimated not to trade in (buy or sell) Equity Shares of the Company during the stated period. </p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
| 06-Mar-2024 | Clarification Sought from Astec Lifesciences Ltd | The Exchange has sought clarification from Astec Lifesciences Ltd on March 6, 2024, with reference to Movement in Volume. The reply is awaited. |
| 12-Feb-2024 | Appointment of CEO | Inter alia, approved:- (a) RE-APPOINTMENT OF MR. ANURAG ROY (DIN: 07444595) AS THE ?WHOLE-TIME DIRECTOR & CHIEF EXECUTIVE OFFICER? FOR A FURTHER TERM OF 3 (THREE) YEARS WITH EFFECT FROM 28TH JULY, 2024 UPTO 27TH JULY, 2027, SUBJECT TO THE APPROVAL OF SHAREHOLDERS: The Board of Directors of the Company, based on the recommendation of the Nomination and Remuneration Committee of the Board of Directors, has re-appointed Mr. Anurag Roy [Director Identification Number (DIN): 07444595] as the ?Whole Time Director & Chief Executive Officer? for a term of 3 (Three) years with effect from 28th July, 2024 upto 27th July, 2027 and approved the remuneration payable to him in such capacity. The re- appointment of Mr. Anurag Roy as the ?Whole Time Director & Chief Executive Officer? for a term of 3 (Three) years with effect from 28th July, 2024 upto 27th July, 2027 is subject to approval of the Shareholders of the Company. |
| 11-Jan-2024 | Astec Lifesciences informs about compliances-certificate | <div style="text-align: justify;">Astec Lifesciences has enclosed compliance certificate received from Bigshare Services, Registrar and Share Transfer Agent of Astec LifeSciences, for the Quarter ended 31st December, 2023, pursuant to Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div><div style="text-align: justify;"><br></div> |
| 23-Aug-2023 | Astec Lifesciences raises Rs 49 crore through NCDs | <p style="text-align: justify;">Astec Lifesciences has raised Rs 49 crore through the allotment of 4,900 Rated, Listed, Unsecured, Redeemable, Non-Convertible Debentures (NCDs) having a face value of Rs 1,00,000 each, to an eligible investor. The Managing Committee of the Board of Directors of the Company at their meeting held on August 22, 2023, has allotted the same. </p><p style="text-align: justify;">Astec Lifesciences manufactures a wide range of agrochemicals and pharmaceutical intermediates.</p><div style="text-align: justify;"><br></div> |
| 02-Aug-2023 | Astec Lifesciences informs about disclosure | <p style="text-align: justify;">Astec Lifesciences has informed that the exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for ICICI Prudential Mutual Fund.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
